3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
11
Recruiting
2
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
2
Sarcoma
1
Other hematologic neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pinealoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Medulloblastoma
1
Histiocytosis, Langerhans-Cell
1
Ependymoma
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Temozolomide
59
Radiotherapy
37
Magnetic Resonance Spectroscopy
32
Radiosurgery
27
Specimen Handling
23
Cyclophosphamide
21
pembrolizumab
20
Nivolumab
20
Radiation
17
Carboplatin
12
Biopsy
12
Bevacizumab
11
Vincristine
10
Ipilimumab
10
Cisplatin
10
X-Rays
9
Lomustine
8
Irinotecan
8
Immunoglobulin G
8
Etoposide
8
trametinib
7
Disulfides
7
AZD 6244
7
pertuzumab
6
atezolizumab
6
abemaciclib
6
Topotecan
6
Proton Therapy
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Celecoxib
×
CNS
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled